These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33592817)

  • 1. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
    Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
    Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H; Chen H; Zhang Y; Cui Y
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
    Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
    Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
    Staskin D; Owens-Grillo J; Thomas E; Rovner E; Cline K; Mujais S
    J Urol; 2024 Aug; 212(2):256-266. PubMed ID: 38708869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
    Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vibegron (Gemtesa) for overactive bladder.
    Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
    [No Abstract]   [Full Text] [Related]  

  • 9. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of the novel β
    Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
    Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating vibegron for the treatment of overactive bladder.
    Rechberger T; Wróbel A
    Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of novel β
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
    Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.